LeonaBio (LONA) Free Cash Flow (2019 - 2026)
LeonaBio (LONA) reported Free Cash Flow of -$20.9 million for Q1 2026, down 42.54% year-over-year from -$36.4 million in Q1 2025, and down 7.76% on a QoQ basis from -$19.4 million in Q4 2025.
LeonaBio (LONA) has 8 years of Free Cash Flow data on file, last reported at -$20.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 42.54% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.0 million (up 39.61% YoY) and the FY2025 annual result came in at -$45.7 million, up 52.96% from the prior year.
- Free Cash Flow fell to -$20.9 million in Q1 2026 per LONA's latest filing, from -$19.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.7 million in Q3 2025 and bottomed at -$26.4 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$21.9 million (2022), against an average of -$19.9 million.
- The widest annual swing landed in 2022, when Free Cash Flow plunged 152.2%; it then jumped 79.72% in 2025.
- Tracing LONA's Free Cash Flow over 5 years: stood at -$15.7 million in 2022, then slumped by 67.81% to -$26.3 million in 2023, then climbed by 1.06% to -$26.0 million in 2024, then grew by 25.43% to -$19.4 million in 2025, then fell by 7.76% to -$20.9 million in 2026.
- Per Business Quant, the three latest LONA Free Cash Flow figures stand at -$20.9 million (Q1 2026), -$19.4 million (Q4 2025), and -$4.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | -20.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.90 Mn |
| Mar 31, 2026 | -20.90 Mn |
| Dec 31, 2025 | -19.40 Mn |
| Dec 31, 2025 | -19.40 Mn |
| Sep 30, 2025 | -4.67 Mn |
| Sep 30, 2025 | -4.67 Mn |
| Jun 30, 2025 | -7.00 Mn |
| Jun 30, 2025 | -7.00 Mn |
| Mar 31, 2025 | -14.67 Mn |
| Mar 31, 2025 | -14.67 Mn |
| Dec 31, 2024 | -26.01 Mn |
| Dec 31, 2024 | -26.01 Mn |
| Sep 30, 2024 | -23.02 Mn |
| Sep 30, 2024 | -23.02 Mn |
| Jun 30, 2024 | -22.36 Mn |
| Jun 30, 2024 | -22.36 Mn |
| Mar 31, 2024 | -25.81 Mn |
| Mar 31, 2024 | -25.81 Mn |
| Dec 31, 2023 | -26.29 Mn |
| Dec 31, 2023 | -26.29 Mn |
| Sep 30, 2023 | -24.01 Mn |
| Sep 30, 2023 | -24.01 Mn |
| Jun 30, 2023 | -24.32 Mn |
| Jun 30, 2023 | -24.32 Mn |
| Mar 31, 2023 | -26.44 Mn |
| Mar 31, 2023 | -26.44 Mn |
| Dec 31, 2022 | -15.67 Mn |
| Dec 31, 2022 | -15.67 Mn |
| Sep 30, 2022 | -21.88 Mn |
| Sep 30, 2022 | -21.88 Mn |
| Jun 30, 2022 | -18.74 Mn |
| Jun 30, 2022 | -18.74 Mn |
| Mar 31, 2022 | -17.32 Mn |
| Mar 31, 2022 | -17.32 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -10.43 Mn |
| Sep 30, 2021 | -10.43 Mn |
| Jun 30, 2021 | -7.43 Mn |
| Jun 30, 2021 | -7.43 Mn |
| Mar 31, 2021 | -7.61 Mn |
| Mar 31, 2021 | -7.61 Mn |
| Dec 31, 2020 | -10.93 Mn |
| Dec 31, 2020 | -10.93 Mn |
| Sep 30, 2020 | -9.41 Mn |
| Sep 30, 2020 | -9.41 Mn |
| Jun 30, 2020 | -2.86 Mn |
| Jun 30, 2020 | -2.86 Mn |
| Mar 31, 2020 | -1.18 Mn |
| Mar 31, 2020 | -1.18 Mn |
| Dec 31, 2019 | -1.03 Mn |
| Dec 31, 2019 | -1.03 Mn |